Immunosuppression in kidney transplant recipients with COVID-19 infection – where do we stand and where are we heading?

References

• Nair V, Jandovitz N, Hirsch JS, et al. COVID-19 in kidney transplant recipients. Am J Transplant. 2020;20(7):1819–1825.
   PubMed Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629.
   PubMed Web of Science ®Google Scholar
• Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):327–331.
   PubMed Web of Science ®Google Scholar
• NasrAllah MM, Osman NA, Elalfy M, Malvezzi P, et al. Transplantation in the era of the Covid-19 pandemic: how should transplant patients and programs be handled? Rev Med Virol. 2020:e2149–e2149.
   PubMed Web of Science ®Google Scholar
• Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. 2020 Jul 17:NEJMoa2021436. doi:10.1056/NEJMoa2021436
   Google Scholar
• Johnson KM, Belfer JJ, Peterson GR, et al. Managing COVID-19 in renal transplant recipients: a review of recent literature and case supporting corticosteroid-sparing immunosuppression. Pharmacotherapy. 2020;40(6):517–524.
   PubMed Web of Science ®Google Scholar
• Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343.
   PubMed Web of Science ®Google Scholar
• Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31(4):304–309.
   PubMed Web of Science ®Google Scholar
• Xiao JZ, Ma L, Gao J, et al. [Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy]. Zhonghua Nei Ke Za Zhi. 2004;43(3):179–182.
   PubMedGoogle Scholar
• Li YM, Wang SX, Gao HS, et al. [Factors of avascular necrosis of femoral head and osteoporosis in SARS patients' convalescence]. Zhonghua Yi Xue Za Zhi. 2004;84(16):1348–1353.
   PubMedGoogle Scholar
• Russell B, Moss C, George G, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020;14:1022–1022.
   PubMed Web of Science ®Google Scholar
• Huang J, Lin H, Wu Y, et al. COVID-19 in posttransplant patients-report of 2 cases. Am J Transplant. 2020;20(7):1879–1881.
   PubMed Web of Science ®Google Scholar
• Zhu L, Xu X, Ma K, et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. Am J Transplant. 2020;20(7):1859–1863.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Zhang Q, Xia H, et al. Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients. Am J Transplant. 2020;20(7):1916–1921.
   PubMed Web of Science ®Google Scholar
• Chen S, Yin Q, Shi H, et al. A familial cluster, including a kidney transplant recipient, of Coronavirus Disease 2019 (COVID-19) in Wuhan, China. Am J Transplant. 2020;20(7):1869–1874.
   PubMed Web of Science ®Google Scholar
• Alberici F, Delbarba E, Manenti C, et al. Management of patients on dialysis and with kidney transplantation during the SARS-CoV-2 (COVID-19) pandemic in Brescia, Italy. Kidney Int Rep. 2020;5(5):580–585.
   PubMed Web of Science ®Google Scholar
• López V, Vázquez T, Alonso-Titos J, et al. Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients. Nefrología (English Edition). 2020;40(3):265–271.
   PubMed Web of Science ®Google Scholar
• Carbajo-Lozoya J, Müller MA, Kallies S, et al. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. Virus Res. 2012;165(1):112–117.
   PubMed Web of Science ®Google Scholar
• de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol. 2011;92(Pt 11):2542–2548.
   PubMed Web of Science ®Google Scholar
• Pfefferle S, Schöpf J, Kögl M, et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 2011;7(10):e1002331.
   PubMed Web of Science ®Google Scholar
• Hage R, Steinack C, Schuurmans MM. Calcineurin inhibitors revisited: a new paradigm for COVID-19? Braz J Infect Dis. 2020;24(4):365–367.
   PubMed Web of Science ®Google Scholar
• Willicombe M, Thomas D, McAdoo S. COVID-19 and calcineurin inhibitors: should they get left out in the storm? J Am Soc Nephrol. 2020;31(6):1145–1146.
   PubMed Web of Science ®Google Scholar
• Solanich X. Clinical trial to evaluate methylprednisolone pulses and tacrolimus in patients with COVID-19 lung injury (TACROVID). 2020.
   Google Scholar
• Coates PT, Wong G, Drueke T, et al. Early experience with COVID-19 in kidney transplantation. Kidney Int. 2020;97(6):1074–1075.
   PubMed Web of Science ®Google Scholar
• Kemmner S, Guba MO, Schönermarck U, et al. Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection. Kidney Int. 2020;98(2):507–508.
   PubMedGoogle Scholar
• Rodriguez-Cubillo B, de la Higuera MAM, Lucena R, et al. Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2? Am J Transplant. 2020 Nov;20(11):3173–3181. doi:10.1111/ajt.16141
   PubMedGoogle Scholar
• van Maarseveen EM, Rogers CC, Trofe-Clark J, et al. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review. AIDS Patient Care Stds. 2012;26(10):568–581.
   PubMed Web of Science ®Google Scholar
• Meziyerh S, Zwart TC, van Etten RW, et al. Severe COVID-19 in a renal transplant recipient: a focus on pharmacokinetics. Am J Transplant. 2020;20(7):1896–1901.
   PubMed Web of Science ®Google Scholar
• Finielz P, Gendoo Z, Chuet C, et al. Interaction between cyclosporin and chloroquine. Nephron. 1993;65(2):333.
   PubMed Web of Science ®Google Scholar
• Nampoory MR, Nessim J, Gupta RK, et al. Drug interaction of chloroquine with ciclosporin. Nephron. 1992;62(1):108–109.
   PubMed Web of Science ®Google Scholar
• Chen D, Yang B, Zhang Y, et al. Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19: A case report. Medicine (Baltimore)). 2020;99(24):e20481.
   PubMed Web of Science ®Google Scholar
• Hart BJ, Dyall J, Postnikova E, et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol. 2014;95(3):571–577.
   PubMed Web of Science ®Google Scholar
• Cheng KW, Cheng SC, Chen WY, et al. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res. 2015;115:9–16.
   PubMed Web of Science ®Google Scholar
• Barbar SD, Clere-Jehl R, Bourredjem A, et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. N Engl J Med. 2018;379(15):1431–1442.
   PubMed Web of Science ®Google Scholar
• Shen L, Niu J, Wang C, et al. High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses. J Virol. 2019;93(12):e00023–00019.
   PubMed Web of Science ®Google Scholar
• Kato F, Matsuyama S, Kawase M, et al. Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2. Microbiol Immunol. 2020;64(9):635–639.
   PubMed Web of Science ®Google Scholar
• Chan JF, Yao Y, Yeung ML, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904–1913.
   PubMed Web of Science ®Google Scholar
• Marx D, Moulin B, Fafi-Kremer S, et al. First case of COVID-19 in a kidney transplant recipient treated with belatacept. Am J Transplant. 2020;20(7):1944–1946.
   PubMed Web of Science ®Google Scholar
• Ahmad SH, Smith R, Camilleri B. Belatacept, kidney transplantation and COVID-19: successful management of the first reported case within the United Kingdom. Clin Transplant. 2020;34(9):e14026.
   PubMed Web of Science ®Google Scholar
• Tavares MR, Pavan IC, Amaral CL, et al. The S6K protein family in health and disease. Life Sci. 2015;131:1–10.
   PubMed Web of Science ®Google Scholar
• Soliman K, Mogadam E, Laftavi M, et al. Long-term outcomes following sirolimus conversion after renal transplantation. Immunol Invest. 2014;43(8):819–828.
   PubMed Web of Science ®Google Scholar
• Mao Z, Zhang W. Role of mTOR in glucose and lipid metabolism. Int J Mol Sci. 2018;19(7):2043.
   Web of Science ®Google Scholar
• Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. Expression of S6K1 in human visceral adipose tissue is upregulated in obesity and related to insulin resistance and inflammation. Acta Diabetol. 2015;52(2):257–266.
   PubMed Web of Science ®Google Scholar
• Le Bacquer O, Petroulakis E, Paglialunga S, et al. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest. 2007;117(2):387–396.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757–767.
   PubMed Web of Science ®Google Scholar
• NIH. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2020.
   Google Scholar
• Analysis C. www.flccc.net. Front line Covid-19 critical care alliance. Review of the emerging evidence supporting the efficacy of Ivermectin in the prophylaxis and treatment of COVID-19. [FLCCC Alliance; updated Jan 12, 2021]
   Google Scholar
• Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
   PubMed Web of Science ®Google Scholar
• Pérez-Sáez MJ, Blasco M, Redondo-Pachón D, et al. Use of tocilizumab in kidney transplant recipients with COVID-19. Am J Transplant. 2020;20(11):3182–3190.
   PubMed Web of Science ®Google Scholar
• Samaee H, Mohsenzadegan M, Ala S, et al. Tocilizumab for treatment patients with COVID-19: recommended medication for novel disease. Int Immunopharmacol. 2020;89:107018.
   PubMed Web of Science ®Google Scholar
• Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. New Eng J Med. 2020 Oct 28;NEJMoa2029849. doi:10.1056/NEJMoa2029849
   Google Scholar
• Mahase E. Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted patients. BMJ. 2020;371:m4362.
   PubMedGoogle Scholar
• Daoud AM, Soliman KM, Ali HK. Potential limitations of plasmapheresis in treatment of COVID-19 patients: how to overcome them? Ther Apher Dial. 2020. doi:10.1111/1744-9987.13568
   PubMedGoogle Scholar
• Chen G, Zhou Y, Ma J, et al. Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients? Ren Fail. 2020;42(1):483–488.
   PubMed Web of Science ®Google Scholar
• Jiang J, Miao Y, Zhao Y, et al. Convalescent plasma therapy: helpful treatment of COVID-19 in a kidney transplant recipient presenting with serve clinical manifestation and complex complications. Clin Transplant. 2020;34(9):e14025.
   PubMed Web of Science ®Google Scholar
• Khamis F, Al-Zakwani I, Al Hashmi S, et al. Therapeutic plasma exchange in adults with severe COVID-19 infection. Int J Infect Dis. 2020;99:214–218.
   PubMed Web of Science ®Google Scholar
• Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol. 2020;16(6):308–310.
   PubMed Web of Science ®Google Scholar
• Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;92(7):791–796.
   PubMed Web of Science ®Google Scholar
• Zarbock A, Kellum JA, Schmidt C, et al. Effect of early vs. delayed initiation of renal replacement therapy on mortality in critically Ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA. 2016;315(20):2190–2199.
   PubMed Web of Science ®Google Scholar
• Quenot JP, Binquet C, Vinsonneau C, et al. Very high volume hemofiltration with the cascade system in septic shock patients. Intensive Care Med. 2015;41(12):2111–2120.
   PubMed Web of Science ®Google Scholar
• Goodman JL, Grabenstein JD, Braun MM. Answering key questions about COVID-19 Vaccines. JAMA. 2020;324(20):2027–2028.
   PubMed Web of Science ®Google Scholar
• Kaur SP, Gupta V. COVID-19 Vaccine: a comprehensive status report. Virus Res. 2020;288:198114.
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951–960.
   PubMed Web of Science ®Google Scholar
• Bos R, Rutten L, van der Lubbe JEM, et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines. 2020;5(1):91.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279.
   PubMed Web of Science ®Google Scholar
• Thng ZX, De Smet MD, Lee CS, et al. COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs. Br J Ophthalmol. 2020 Jun 12;bjophthalmol-2020-316586. doi:10.1136/bjophthalmol-2020-316586
   PubMed Web of Science ®Google Scholar
• Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95.
   PubMed Web of Science ®Google Scholar
• Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.
   PubMed Web of Science ®Google Scholar
• Chinese CNHC. Clinical guidance for COVID-19 pneumonia diagnosis and treatment. ACC news story. 2020. http://kjfy.meetingchina.org/msite/news/show/cn/3337.html
   Google Scholar
• Lombardia SSIdMIeTSR. Vademecum per la cura delle persone con malattia da COVI-19 [Vademecum for the care of people with COVID-19 disease]. 2020 Jun 1;28(2):143–152. https://pubmed.ncbi.nlm.nih.gov/32275256/.
   Google Scholar